Determinants for prediction of malignant potential by metalloproteinase:E- cadherin ratio in prostate core needle biopsy

Pathobiology

Volumn 73, Issue 2, 2006, Pages 98-104

  Ohmori, H ^a,d   Fujii, K ^a   Sasahira, T ^a   Ukai, R ^b   Ikeda, M ^c   Kobayashi, K ^c   Maruyama, A ^c   Kuniyasu, H ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA GENERAL HOSPITAL   (Japan)

^c Miyoshi Central Hospital   (Japan)

^d Okayama Gakuin University   (Japan)

Author keywords

Cancer heterogeneity; E cadherin; Malignant potential; Matrix metalloproteinase; Prostate cancer

Indexed keywords

METALLOPROTEINASE; UVOMORULIN;

ARTICLE; CANCER CYTODIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ERROR; GLEASON SCORE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; NEEDLE BIOPSY; PATHOLOGY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

BIOPSY, NEEDLE; CADHERINS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; REFERENCE VALUES; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 33748278536     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094494     Document Type: Article

References (22)

1. Kuniyasu H, Troncoso P, Johnston D, Bucana CD, Tahara E, Fidler IJ, et al: Relative expression of type IV collagenae, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000;6:2295-2308.
2. Kuniyasu H, Ukai R, Johnston D, Troncoso P, Fidler IJ, Pettaway CA: The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res 2003;9:2185-2194.
3. Kuniyasu H, Ellis LM, Evans DB, Abbruzzese JL, Fenoglio CJ, Bucana CD, et al: Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res 1999;5:25-33.
4. Kitadai Y, Ellis LM, Tucker SL, Green GF, Bucana CD, Cleary KR, et al: Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol 1996;149:1541-1551.
5. Anzai H, Kitadai Y, Bucana CD, Sanchez R, Omoto R, Fidler IJ: Intratumoral heterogeneity and inverse correlation between expression of E-cadherin and collagenase type IV in human gastric carcinomas. Differentiation 1996;60:119-127.
6. Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, et al: Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small celllung carcinoma. Clin Cancer Res 2000;6:790-797.
7. Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-128.
8. Gleason DF, Mellinger GT; Veterans Administrative Cooperative Urologic Research Group: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
9. Mellinger GT, Gleason DF, Bailar J: The histology and prognosis of prostate cancer. J Urol 1967;97:331-337.
10. Oesterling JE, Brendler CB, Epstein JI, Kimball AW, Walsh PC: Correlation of clinical stage, serum prostatic acid phosphatase, and preoperative Gleason grade with final pathologic stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 1987;138:92-98.
11. Fowler JE, Mills SE: Operable prostatic carcinoma: correlations among clinical stage, pathological stage, Gleason histological score, and early disease-free survival. J Urol 1985;133:49-52.
12. Gleason DF, Mellinger GT; Veterans Administrative Cooperative Urologic Research Group: Histologic grading and clinical staging of prostatic carcinoma; in Tannenbaum M (ed): Urologic Pathology: the Prostate. Philadelphia, Lea & Febiger, 1977.
13. Sogani PC, Israel A, Lieberman PH, Lesser ML, Whitmore WF: Gleason grading of prostate cancer: a predictor of survival. Urology 1985;25:223-227.
14. Fleming ID, Cooper JS, Henson DE, Hutter RVP, Kennedy BJ, Murphy GP, et al: AJCC Cancer Staging Manual. Philadelphia, Lippincott-Raven, 1997.
15. Gleason DF, Mellinger GT; Veterans Administrative Cooperative Urologic Research Group: Histologic grading and clinical staging of prostate carcinoma; in Tannenbaum M (ed): The Prostate. Philadelphia, Lea & Febiger, 1998.
16. Bucana CD, Radinsky R, Dong Z, Sanchez R, Brigati DJ, Fidler IJ: A rapid colorimetric in situ mRNA hybridization technique using hyperbiotinylated oligonucleotide probes for analysis of mdr-1 in mouse colon carcinoma cells. J Histochem Cytochem 1993;41:499-506.
17. Park C-S, Manahan LJ, Brigati DJ: Automated molecular pathology: one hour in situ DNA hybridization. J Histotechnol 1991;14:219-229.
18. Reed JA, Manahan LJ, Park CS, Brigati DJ: Complete one-hour immunocytochemistry based on capillary action. Biotechniques 1992;13:434-443.
19. Cookson MS: Update on transrectal ultrasound-guided needle biopsy of the prostate. Mol Urol 2000;4:93-98.
20. Djavan B, Zlotta AR, Ekane S, Remzi M, Kramer G, Roumeguere T, et al: Is one set of sextant biopsies enough to rule out prostate cancer? Influence of transition and total prostate volumes on prostate cancer yield. Eur Urol 2000;38:218-224.
21. Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, et al: A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 2000;163:152-157.
22. Rovner ES, Schanne FJ, Malkowicz SB, Wein AJ: Transurethral biopsy of the prostate for persistently elevated or increasing prostate specific antigen following multiple negative transrectal biopsies. J Urol 1997;158:138-141.